Company OptiNose, Inc.

OPTN

US68404V1008

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for OptiNose, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.8942 ^USD	-3.61%		-26.70%	-30.68%

Mar. 18	Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	MT
Mar. 18	Sector Update: Health Care Stocks Steady Premarket Monday	MT

OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Number of employees: 132

USD in Million	2022	Weight	2023	Weight	Delta
Products fo Patients Treated by Ear, Nose and Throat and Allergy Specialists 100.0 %	76	100.0 %	71	100.0 %	-6.93%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	76	100.0 %	71	100.0 %	-6.93%

Managers	Title	Age	Since
Ramy Mahmoud CEO	Chief Executive Officer	59	09-12-31
Michael C. Berkey CTO	Chief Tech/Sci/R&D Officer	-	17-05-31
John C. Messina CTO	Chief Tech/Sci/R&D Officer	-	09-12-31
Jonathan Neely IRC	Investor Relations Contact	-	17-11-30
Paul Spence PRN	Corporate Officer/Principal	56	22-12-14
Anthony Kirck AUD	Comptroller/Controller/Auditor	43	21-10-31
Ramona M. Lloyd LAW	General Counsel	-	14-06-11
Michael Marino LAW	General Counsel	48	16-12-31
Karen Brophy HRO	Human Resources Officer	60	18-01-31

Members of the board	Title	Age	Since
Wilhelmus Groenhuysen BRD	Director/Board Member	66	17-09-30
Sandra Helton BRD	Director/Board Member	74	18-02-21
Eric Bednarski BRD	Director/Board Member	53	21-12-09
R. Fletcher CHM	Chairman	78	22-04-25
Ramy Mahmoud CEO	Chief Executive Officer	59	09-12-31
Tomas Jan Heyman BRD	Director/Board Member	68	20-11-30
Kyle Dempsey BRD	Director/Board Member	35	21-12-09
Catherine Owen BRD	Director/Board Member	-	20-07-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	112,651,740	102,546,895 ( 91.03 %)	0	91.03 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 13.02 %	14,666,941	13.02 %	21 M $
MVM Partners LLC 12.96 %	14,605,263	12.96 %	21 M $
Jeffrey Robert Jay 7.847 %	8,839,939	7.847 %	13 M $
Theodore Kruttschnitt 6.471 %	7,290,000	6.471 %	11 M $
Acorn Capital Advisors LLC 6.018 %	6,778,851	6.018 %	10 M $
Rosalind Advisors, Inc. 4.337 %	4,885,580	4.337 %	7 M $
BlackRock Advisors LLC 3.758 %	4,232,969	3.758 %	6 M $
Vanguard Fiduciary Trust Co. 3.710 %	4,179,704	3.710 %	6 M $
Bleichroeder LP 3.591 %	4,045,132	3.591 %	6 M $
Kingdon Capital Management LLC 3.461 %	3,899,237	3.461 %	6 M $

OptiNose, Inc.

1020 Stony Hill Road Suite 300

19067, Yardley

+267 364 3500

http://www.optinose.com

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9277 USD

Average target price

3.75 USD

Spread / Average Target

+304.23%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
OPTINOSE, INC.	-30.68%	105M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals